Pulmatrix, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing was signed March 23, 2021. Pulmatrix is a clinical-stage biotechnology company developing inhaled therapies using its iSPERSE dry-powder delivery platform; it has no products approved for sale and generated no product-sale revenue.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $12.634 million | $7.910 million |
| Research and development expense | $15.609 million | $12.845 million |
| General and administrative expense | $6.887 million | $8.489 million |
| Total operating expenses | $22.496 million | $28.602 million |
| Operating loss | $9.862 million | $20.692 million |
| Net loss | $19.308 million | $20.596 million |
| Basic and diluted loss per share | $0.67 | $1.23 |
| Net cash used in operating activities | $12.483 million | Net cash provided: $3.230 million |
- Revenue was primarily collaboration and license income from Cipla and JJEI, plus immaterial royalties from Sensory Cloud; it does not represent sales of Pulmatrix products.
- At year-end, cash and cash equivalents were $31.657 million, with $204,000 of restricted cash. Accumulated deficit was $234.469 million. Total liabilities were $15.030 million, including deferred revenue and lease liabilities; the balance sheet reports no term-loan balance.
- Management said existing resources were expected to fund planned operations for at least 12 months after filing, while warning that assumptions could prove wrong and additional capital would be needed to continue development at current spending levels.
- In February 2021, after year-end, Pulmatrix raised $40.0 million gross in a registered direct offering of 20 million shares, before fees and expenses. The filing does not provide the resulting net proceeds.
Changes from 2019
- Revenue increased $4.724 million, mainly from JJEI agreement revenue, partly offset by lower Cipla revenue.
- R&D expense rose $2.764 million, reflecting increased PUR1800 and PUR3100 development, manufacturing, and personnel costs, partly offset by lower Pulmazole Phase 2 costs.
- G&A expense declined $1.602 million. The 2019 period included a $7.268 million goodwill impairment; there was no impairment in 2020.
- Net loss improved by $1.288 million, but 2020 included a $9.289 million non-cash warrant inducement expense. Operating cash flow moved from a $3.230 million inflow to a $12.483 million outflow, in part because deferred revenue declined.
Programs, outlook, and material risks
- Pulmazole: The Phase 2 study for ABPA in asthma was terminated in July 2020 after COVID-19 disrupted enrollment and study conduct. Following a January 2021 FDA Type C meeting, the company planned a Phase 2b study with a 16-week dosing regimen, subject to more favorable pandemic conditions. Cipla amendment discussions remained unresolved at filing; failure to agree on matters such as cost sharing could suspend further development.
- PUR1800: The first patient entered a Phase 1b study in stable moderate-to-severe COPD in February 2021; data were anticipated in Q4 2021. JJEI holds an option to license the program. Potential payments include a $2.0 million study-completion milestone and, if the option is exercised, an option payment and further development and commercial milestones, plus royalties. These are contingent, not assured proceeds.
- PUR3100: The company planned additional preclinical safety work in 2021 and a Phase 1/Phase 2 study start in Q1 2022, subject to completing development and regulatory steps.
- Other collaboration: Sensory Cloud launched FEND, which uses licensed NasoCalm technology, in Q4 2020; Pulmatrix recorded immaterial royalty revenue for the period. The agreement provides tiered royalties and a $1.0 million milestone if aggregate licensed-product sales reach $20.0 million.
- Key risks: Recurring losses and operating cash burn create ongoing financing needs and potential dilution; clinical and regulatory outcomes are uncertain; COVID-19 may delay trials; Pulmazole’s future depends in part on unresolved Cipla discussions; PUR1800 depends on trial results and JJEI’s option decision; and the company relies on third-party manufacturers, suppliers, CROs, and collaborators. Management reported no material legal proceedings and no material off-balance-sheet arrangements.
Important facts for investors to verify
- Current cash, net proceeds and cash runway after the February 2021 offering, including subsequent spending and financing needs.
- Whether Pulmatrix and Cipla reached amended terms, agreed on Phase 2b funding and cost sharing, and restarted Pulmazole development.
- PUR1800 Phase 1b results, completion of the supporting toxicology work, and whether JJEI exercised or terminated its option.
- PUR3100’s preclinical progress and whether the anticipated IND and early-2022 study timeline remained achievable.
- Future collaboration revenue recognition, Sensory Cloud sales and royalties, and any milestone payments actually earned.
- Potential dilution from equity issuance, warrants and options; year-end common shares outstanding were 36.1 million, with 23.3 million warrants outstanding.